Clinical trial Recruiting at 1 site Observational Ages 18 to 90

Remote assessment for people with Parkinson's disease

Official title: PD Frontline, Part of RAPSODI GD (Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher's Disease) to Build an Online Trial-ready Cohort of GBA Genotyped People With Parkinson's

Run by University College, London · NCT06151002 · Data updated 2026-11-12

This study is testing whether an online questionnaire and saliva samples can help people with Parkinson's disease learn about their genetics and find out if they might qualify for future clinical trials.

Quick facts

Study typeObservational
Ages18 Years to 90 Years
SexAll
Enrollment20000 (estimated)
SponsorUniversity College, London
Academic / other
Locations1 site (London)
StatusRecruiting
StartedFebruary 15, 2020
Main results expectedJanuary 1, 2028
Study endsAugust 20, 2040
Registry record updatedOctober 29, 2026
Trial IDNCT06151002 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals with a formal diagnosis of Parkinson's disease who do not carry a GBA variant.

Probably not a fit

Patients with a confirmed GBA variant or those with other neurological disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PD Frontline is an observational study aimed at preparing individuals with Parkinson's disease for participation in clinical trials. Participants complete an online questionnaire and receive a saliva collection kit to provide samples for genetic testing of the GBA1 and LRRK2 genes, which are associated with Parkinson's disease. The study seeks to identify potential candidates for gene-targeted trials and keep participants informed about relevant research opportunities based on their genetic results.

Why it matters

Potential benefit: If successful, this study could enhance the recruitment of patients for targeted therapies in Parkinson's disease.

How similar studies have gone: Other studies focusing on genetic testing in Parkinson's disease have shown promise, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Formal diagnosis of Parkinson Disease

Exclusion Criteria:

* Confirmation that the individual carries a GBA1 variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.
* History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration)
* Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease.
* Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).

Where it's running

  • University College London (UCL)
    London, United Kingdom
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.